Table 2.
Criteria | E2F1 | E2F2 | E2F3 | E2F4 | E2F5 | E2F6 | E2F7 | E2F8 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||
No.a | mRNA | P-value | mRNA | P-value | mRNA | P-value | mRNA | P-value | mRNA | P-value | mRNA | P-value | mRNA | P-value | mRNA | P-value | |
Age | |||||||||||||||||
≤51 | 1,361 | – | 0.9623 | – | 0.0284 | – | <0.0001 | – | 0.5265 | – | 0.0377 | – | 0.0004 | – | 0.8497 | – | 0.3461 |
>51 | 2,142 | – | ↓ | ↓ | – | ↓ | ↓ | – | – | ||||||||
Nodal status | |||||||||||||||||
− | 2,447 | – | 0.4376 | – | 0.1055 | – | 0.7359 | – | 0.2055 | – | 0.0246 | – | 0.8244 | – | 0.1139 | – | 0.1536 |
+ | 1,509 | – | – | – | – | ↑ | – | – | – | ||||||||
ER (IHC) | |||||||||||||||||
− | 1,525 | – | <0.0001 | – | <0.0001 | – | <0.0001 | – | 0.0001 | – | <0.0001 | – | 0.4174 | – | <0.0001 | – | <0.0001 |
+ | 3,923 | ↓ | ↓ | ↓ | ↓ | ↓ | – | ↓ | ↓ | ||||||||
PR (IHC) | |||||||||||||||||
− | 946 | – | <0.0001 | – | <0.0001 | – | <0.0001 | – | 0.0097 | – | 0.0919 | – | 0.0282 | – | 0.0002 | – | <0.0001 |
+ | 1,439 | ↓ | ↓ | ↓ | ↓ | – | ↓ | ↓ | ↓ | ||||||||
HER2 (IHC) | |||||||||||||||||
− | 1,409 | – | 0.0083 | – | 0.3372 | – | 0.0293 | – | 0.8335 | – | 0.6897 | – | 0.9495 | – | 0.0012 | – | <0.0001 |
+ | 201 | ↑ | – | ↑ | – | – | – | ↑ | ↑ | ||||||||
Triple-negative BC (TNBC) | |||||||||||||||||
Not | 4,099 | – | <0.0001 | – | <0.0001 | – | <0.0001 | – | 0.9164 | – | 0.0007 | – | 0.8832 | – | 0.0251 | – | <0.0001 |
TNBC | 374 | ↑ | ↑ | ↑ | – | ↑ | – | ↑ |
Note:
The number of patients was based on the group of E2F1 and the exact number of patients in other groups may be a little different.
Abbreviations: E2Fs, E2F transcription factors; BC, breast carcinoma; ER, estrogen receptor; IHC, immunohistochemistry; PR, progesterone receptor.